A few nights ago I found myself in an interesting situation - I was at Matt Gonzalez birthday party at his home and the traditional “what do you do for a living” question came up in a conversation circle. For those who don’t know Matt, he is an American liberal politician, lawyer and activist, prominent in San Francisco politics and also the vice presidential candidate for Ralph Nader. The people in the circle were either activists or artists, and when I said that I worked in marketing for the life sciences industry there was no shortage of reproachful looks and one brave man who asked me in a disapproving tone ‘do you mean you work for the pharmaceutical industry?’.
Tags: Personalized Medicine, Product Strategy, Global Strategy
I Google, we all Google, but do you iGoogle? We are all exposed to more and more information from a myriad of sources and for me at least it is a constant challenge to refer to multiple sites and sources while I am working on projects. I have been using iGoogle - essentially a personalized Google home page to perhaps bring the mountain to Mohammed ...
Tags: Google, Transforming Technology, Product Strategey, Global Strategy, Patient Strategy, Web 2.0
The topic of speeding up websites deployed using the Drupal content management system is a well traveled and rich literary landscape. In fact, search the internet for a variety of performance topics, both Drupal specific and more generic and you will find dozens of articles offering advice, techniques and all too often sympathy for your plight. Unfortunately, the wealth of conversation on the topic is a pretty good indication of the need to get information about making Drupal perform.
Tags: Transforming Technology, Patient Strategy, Product Strategy, Global Strategy
I am the CEO of a communications agency that depends directly on DTC and DTP advertising for a significant portion of our bottom line. One of our largest clients is a non-profit patient advocacy group. In addition, we have many, many clients who have to balance their passion for finding cures with their need to satisfy their investors' expectations. As we begin 2008 and listen to the Presidential candidates views on healthcare, we hear a lot of strident voices within industry often pitted against patient advocacy. It seems that there's a lot of talk about change, a lot of serious resistance to change, and a lot of skeptics who say the pharmaceutical industry will never change.
Yesterday, Dr. Judah Folkman, the pioneering cancer researcher whose passion and commitment resulted in a whole new field of medicine, died.
Tags: Product Strategy, Global Strategy, Oncology